36770-50-0

Basic information

• Product Name: 2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE
• Synonyms: Pyridine,2-[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]- (9CI);3-(2-Pyridyl)-5-(4-pyridyl)-1,2,4-triazole
• CAS NO: 36770-50-0
• Molecular Formula: C12H9N5
• Molecular Weight: 223.23
• Mol File: 36770-50-0.mol

Chemical Properties

• Boiling Point: 515.1°Cat760mmHg
• Flash Point: 250.4°C
• Appearance: /
• Density: 1.303g/cm³
• Vapor Pressure: 1.02E-10mmHg at 25°C
• Refractive Index: 1.647
• CAS DataBase Reference: 2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE(36770-50-0)
• EPA Substance Registry System: 2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE(36770-50-0)

Safety Data

• Hazardous Substances Data: 36770-50-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE is used as a building block in organic synthesis for the development of new pharmaceuticals. Its unique structure and properties contribute to the creation of compounds with potential biological activity, including antimicrobial, anticancer, and anti-inflammatory properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE serves as a key component in the synthesis of new agrochemicals. Its ability to form compounds with biological activity makes it valuable for the development of innovative products with applications in agriculture and pest control.
Used in Research and Development:
2-(3-PYRIDIN-4-YL-1H-1,2,4-TRIAZOL-5-YL)PYRIDINE is utilized in research and development for the exploration of its antimicrobial, anticancer, and anti-inflammatory properties. Its potential applications in these areas make it a valuable compound for further investigation and the advancement of medical and chemical sciences.

InChI:InChI=1/C12H9N5/c1-2-6-14-10(3-1)12-15-11(16-17-12)9-4-7-13-8-5-9/h1-8H,(H,15,16,17)

Upstream product

• 100-70-9 2-Cyanopyridine 
• 54-85-3 isoniazid 
• 19547-38-7 methyl pyridine-2-imidate 
• 260447-07-2 C₁₂H₁₁N₅O 

Relevant articles and documents

Structure and excitation-dependent emission of novel zinc complexes with pyridyltriazoles

A series of Zn(ii) complexes with 5-(4-R-phenyl)-3-(pyridin-2-yl)-1,2,4-triazoles have been synthesized and subsequently characterized by single crystal X-ray diffraction, 1H-NMR, FT-IR spectroscopy, elemental analyses, ESI-MS, and PXRD. The X-ray diffraction analyses revealed that the complexes have a similar molecular structure and their supramolecular frameworks are constructed by hydrogen bonds and π?π interaction scaffolds. Upon irradiation with UV light, the studied complexes display deep blue emission at 396-436 nm in the solid state. The compounds show an unexpected excitation-dependent emission phenomenon which is detected by a change in the emission color (from blue to yellow) upon increase of the excitation wavelength. The conducted quantum-chemical calculations indicate that supramolecular differences in the single-crystal architecture of the synthesized complexes play a crucial role for this photophysical behaviour.

Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia

Our previous study identified 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4]triazol-3-yl]-benzonitrile (2) as a safe and potent xanthine oxidoreductase (XOR) inhibitor for the treatment of hyperuricemia. Here, we synthesized a series of 3,5-dipyridyl-1,2,4-triazole derivatives and, in particular, examined their in vivo activity in lowering the serum uric acid levels in rats. As a result, we identified 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole (FYX-051, compound 39) to be one of the most potent XOR inhibitors; it exhibited an extremely potent in vivo activity, weak CYP3A4-inhibitory activity and a better pharmacokinetic profile than compound 2. Compound 39 is currently being evaluated in a phase 2 clinical trial.

Anti-hyperuricemia composition

Compositions useful in the treatment of gout and hyperuricemia and containing a substituted 1,2,4-triazole as the active ingredient are provided, the triazoles being substituted at the 5 position with a pyridyl radical and at the 3 position with a phenyl

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.